Nanexa AB announced that the Clinical Trial Application for the Phase I study of NEX-22 in patients with type 2 diabetes has been received and validated by the European Medicines Agency (EMA).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.045 SEK | -5.00% | +22.65% | -15.04% |
May. 15 | Nanexa AB Elects Hanna Tilus as Members of the Board | CI |
May. 15 | Nanexa AB Receives Approval for NEX-22 Clinical Study | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.04% | 14.15M | |
+4.27% | 211M |
- Stock Market
- Equities
- NANEXA Stock
- News Nanexa AB
- Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA